NCT00254748View on ClinicalTrials.gov

Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

June 30, 2007

Conditions
Borderline Personality Disorder
Interventions
DRUG

Quetiapine fumarate

flexible doses from 200 mg to 600 mg

DRUG

Placebo

placebo

Trial Locations (3)

Unknown

Research Site, Apeldoorn

Research Site, Nijmegen

Research Site, Veghel

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY